Subbarao, K. et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. (N. Y., N. Y.) 279, 393–396 (1998).
Szablewski, C. M. et al. Reported Global Avian Influenza Detections Among Humans and Animals During 2013-2022: Comprehensive Review and Analysis of Available Surveillance Data. JMIR Public Health Surveill. 9, e46383 (2023).
Elsmo, E. J. et al. Highly Pathogenic Avian Influenza A(H5N1) Virus Clade 2.3.4.4b Infections in Wild Terrestrial Mammals, United States, 2022. Emerg. Infect. Dis. 29, 2451–2460 (2023).
Kandeil, A. et al. Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America. Nat. Commun. 14, 3082 (2023).
Kniss, K. et al. Risk for Infection in Humans after Exposure to Birds Infected with Highly Pathogenic Avian Influenza A(H5N1) Virus, United States, 2022. Emerg. Infect. Dis. 29, 1215–1219 (2023).
Uyeki, T. M. et al. Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Dairy Farm Worker. N. Engl. J. Med. 390, 2028–2029 (2024).
Drehoff, C. C. et al. Cluster of Influenza A(H5) Cases Associated with Poultry Exposure at Two Facilities – Colorado, July 2024. Mmwr. Morbidity Mortal. Wkly. Rep. 73, 734–739 (2024).
Morse, J. et al. Influenza A(H5N1) Virus Infection in Two Dairy Farm Workers in Michigan. N. Engl. J. Med. 391, 963–964 (2024).
Garg, S. et al. Outbreak of Highly Pathogenic Avian Influenza A(H5N1) Viruses in U.S. Dairy Cattle and Detection of Two Human Cases – United States, 2024. Mmwr. Morbidity Mortal. Wkly. Rep. 73, 501–505 (2024).
CDC. H5 Bird Flu: Current Situation. https://www.cdc.gov/bird-flu/situation-summary/index.html, accessed Sept 10, 2025 (2025).
CDC. Influenza Risk Assessment Tool (IRAT). https://www.cdc.gov/pandemic-flu/php/monitoring/irat-virus-summaries.html. (2024).
Chen, X. et al. Serological evidence of human infections with highly pathogenic avian influenza A(H5N1) virus: a systematic review and meta-analysis. BMC Med. 18, 377 (2020).
Sun, X. et al. Effect of Prior Influenza A(H1N1)pdm09 Virus Infection on Pathogenesis and Transmission of Human Influenza A(H5N1) Clade 2.3.4.4b Virus in Ferret Model. Emerg. Infect. Dis. 31, 458–466 (2025).
Le Sage, V. et al. Influenza A(H5N1) Immune Response among Ferrets with Influenza A(H1N1)pdm09 Immunity. Emerg. Infect. Dis. 31, 477–487 (2025).
Garretson, T. A. et al. Immune history shapes human antibody responses to H5N1 influenza viruses. Nat. Med. 31, 1454–1458 (2025).
Li, C. K., Rappuoli, R. & Xu, X. N. Correlates of protection against influenza infection in humans-on the path to a universal vaccine?. Curr. Opin. Immunol. 25, 470–476 (2013).
WHO. WHO case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005). https://www.who.int/teams/global-influenza-programme/avian-influenza/case-definitions (2024).
Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065–1070 (2015).
Levine, M. Z. et al. Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity. Vaccines (Basel) 10, 1856 (2022).
Monto, A. S. et al. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J. Infect. Dis. 212, 1191–9 (2015).
Monto, A. S. & Kendal, A. P. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1, 623–625 (1973).
Murphy, B. R., Kasel, J. A. & Chanock, R. M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286, 1329–1332 (1972).
Park, J. K. et al. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus. mBio 9, e02284–17 (2018).
Rockman, S. et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 87, 3053–3061 (2013).
Chen, Y. Q. et al. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. Cell 173, 417–429.e410 (2018).
Daulagala, P. et al. Avian Influenza A(H5N1) Neuraminidase Inhibition Antibodies in Healthy Adults after Exposure to Influenza A(H1N1)pdm09. Emerg. Infect. Dis. 30, 168–171 (2024).
Vavricka, C. J. et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 7, e1002249 (2011).
Wan, H. et al. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nat. Commun. 6, 6114 (2015).
Koutsakos, M. et al. Binding antibody titers against the hemagglutinin and neuraminidase correlate with protection against medically attended influenza A and B disease. J. Virol. 99, e0039125 (2025).
Eichelberger, M. C., Morens, D. M. & Taubenberger, J. K. Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness. Curr. Opin. Immunol. 53, 38–44 (2018).
Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science. (N.Y.) 324, 246–251 (2009).
Krammer, F. & Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167–182 (2015).
Gostic, K. M., Ambrose, M., Worobey, M. & Lloyd-Smith, J. O. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science. (N.Y.) 354, 722–726 (2016).
Edgar, J. E. et al. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo. Proc. Natl Acad. Sci. USA 120, e2314905120 (2023).
Liu, W. C. et al. Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines (Basel) 9, 40 (2021).
Han, A. et al. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 73, e4260–e4268 (2021).
Lim, J. J. et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. Antimicrobial agents Chemother. 64, e00352–20 (2020).
Lim, J. J. et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. Open forum Infect. Dis. 9, ofab630 (2022).
Nachbagauer, R. et al. Induction of broadly-reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88, 13260–8 (2014).
Restori, K. H. et al. Preexisting immunity to the 2009 pandemic H1N1 virus reduces susceptibility to H5N1 infection and disease in ferrets. Sci. Transl. Med. 17, eadw4856 (2025).
Grohskopf, L. A., Ferdinands, J. M., Blanton, L. H., Broder, K. R. & Loehr, J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024-25 Influenza Season. Mmwr. Recommendations Rep.: Morbidity Mortal. Wkly. report. Recommendations Rep./ Cent. Dis. Control 73, 1–25 (2024).
CDC. National Pandemic Strategy https://www.cdc.gov/pandemic-flu/php/national-strategy/index.html. (2024).
Li, Z. N. et al. Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses. J. virological methods 243, 61–67 (2017).
Li, Z. N. et al. Novel multiplex assay platforms to detect influenza A hemagglutinin subtype-specific antibody responses for high-throughput and in-field applications. Influenza other respiratory viruses 11, 289–297 (2017).
Poirot, E. et al. Detection of Avian Influenza A(H7N2) Virus Infection Among Animal Shelter Workers Using a Novel Serological Approach-New York City, 2016–2017. J. Infect.Dis. 219, 1688–1696 (2019).
Li, Z. N. et al. Multiplex Detection of Antibody Landscapes to SARS-CoV-2/Influenza/Common Human Coronaviruses Following Vaccination or Infection with SARS-CoV-2 and Influenza. Clin. Infect. Dis. 75, S271–S284 (2022).
Li, Z. N. et al. Identification of novel influenza A virus exposures by an improved high-throughput multiplex MAGPIX platform and serum adsorption. Influenza Other Resp. Viruses. 14, 129–141 (2020).
Levine, M. et al. Neutralizing Antibody Response to Influenza A(H5N1) Virus in Dairy Farm Workers, Michigan, USA. Emerg. Infect. Dis. J. 31, 876–878 (2025).
Results of Influenza Risk Assessment Tool. https://www.cdc.gov/pandemic-flu/php/monitoring/irat-virus-summaries.html?CDC_AAref_Val=https://www.cdc.gov/flu/pandemic-resources/monitoring/irat-virus-summaries.htm. (2024).
Tenforde, M. W. et al. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 73, e4244–e4250 (2021).
HHS. Regulations for the Protection of Human Subjects in Research. 45 CFR §46 (2018).
Institutional Review Boards. 21 CFR §56 (2020).
Protection of privacy of individuals who are research subjects, 42 USC §241(d) (2011).
Records maintained on individuals, 5 USC §552a (2010).
Paperwork Reduction Act, 44 USC §3501 et seq (1995).
Yang, H., Carney, P. & Stevens, J. Structure and Receptor binding properties of a pandemic H1N1 virus hemagglutinin. PLoS Curr. 2, RRN1152 (2010).
Yang, H. et al. Structural stability of influenza A(H1N1)pdm09 virus hemagglutinins. J. Virol. 88, 4828–4838 (2014).
Li, Z. N. et al. Antibody Landscape Analysis following Influenza Vaccination and Natural Infection in Humans with a High-Throughput Multiplex Influenza Antibody Detection Assay. mBio 12, e02808–20 (2021).
Levine, M. Z. et al. Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans. J. Infect. Dis. 216, S555–s559 (2017).
Levine, M. Z. et al. Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost. NPJ Vaccines 4, 22 (2019).
Network, W.G.I.S. Manual for the labratory diagnosis and virological surveillence of influenza. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf (2011).
Couzens, L. et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J. virological methods 210C, 7–14 (2014).
